Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: The settlements with the patient assistance charities Good Days and Patient Access Network Foundation were the first with foundations linked to an industry-wide probe that has resulted in $840 million in settlements with drugmakers. Both foundations provide assistance to patients seeking to pay out-of-pocket costs for medications. Good Days agreed to pay $2 million while PAN Foundation agreed to pay $4 million. Neither admitted wrongdoing. Good Days in a statement said the settlement will allow it to concentrate on providing help to people in need of life-saving medications. PAN said the settlement involved “legacy matters” rather than its current operations. Drug companies are prohibited from subsidizing co-payments for patients enrolled in the government’s Medicare healthcare program for those aged 65 and older. Companies may donate to non-profits providing co-pay assistance as long as they are independent. But the government has alleged that various drugmakers have used charities like Good Days and PAN as means to improperly pay the co-pay obligations of Medicare patients using their drugs, in violation of the Anti-Kickback Statute. The department said Good Days, previously known as the Chronic Disease Fund, from 2010 to 2014 conspired with companies including Novartis AG, Astellas and Questcor, now owned by Mallinckrodt Plc, to pay kickbacks to Medicare patients using their drugs. Those drugs included H.P. Acthar Gel, an expensive treatment for a rare infant seizure disorder and multiple sclerosis that is subject of a related lawsuit by the government against Mallinckrodt over Questcor’s donations to the charity. The Justice Department said Questcor from 2010 to 2014 used the charity as a conduit to improperly subsidize patients’ copays, allowing it to keep raising prices for Acthar, whose price increased from $50 per vial in 2001 to $32,200 in 2014. Mallinckrodt declined to comment. It has said it believed its actions were lawful. PAN similarly permitted Bayer AG, Astellas, Dendreon Pharmaceuticals and Amgen Inc to use it as a conduit to pay patients kickbacks, according to the government’s allegations. Astellas and Amgen in April agreed to pay $100 million and $24.75 million, respectively, to resolve related claims. Dendreon said it takes compliance seriously. Novartis declined to comment. The other companies’ representatives did not respond to requests for comment.
Example Output: Two charities to pay $6 million to resolve U.S. pharma kickback probe.

Example Input: The story says the federal government is paying about $2,250 per patient for a standard 5-day treatment course. It also notes that the approved alternative treatments are less expensive. The story points out that the benefits of peramivir have yet to be proven and that it is being offered only because some patients are not helped by approved drugs or are they are so sick they need a drug that can be given intravenously. The approved antiviral drugs are currently available only in pill or inhaled form. The story should have mentioned the side effects seen in clinical trials so far, as well as the risk that patients could suffer harms like those sometimes seen in people who have been given similar antiviral drugs. These side effects are clearly spelled out in an FDA fact sheet prepared for patients and caregivers: “The most common side effects of PERAMIVIR are: • diarrhea • nausea • vomiting • white blood cell count decreased These side effects may go away after you stop receiving PERAMIVIR. These are not all the possible side effects of PERAMIVIR. Peramivir is still being studied so it is possible that all of the risks are not known at this time. Other medicines that are used to treat people with 2009 H1N1 flu have side effects that may also happen in people who receive PERAMIVIR. These side effects include: • Signs of unusual behavior. People with the flu, especially children and adolescents, may be at a higher risk for seizures, confusion, or abnormal behavior early in their illness. These events may happen after starting PERAMIVIR or may happen if the flu is not treated. These events are not common. Patients should be watched for signs of unusual behavior. • Allergic reaction or severe rash Not a lot of people have taken PERAMIVIR for 5 days or longer. Serious and unexpected side effects may happen. The side effects of getting any medicine by vein are brief pain, bleeding, bruising of the skin where the needle enters, soreness and swelling at that spot, and possible infection at that spot.”  Patient fact sheet available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187799.pdf Provider fact sheet available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf The story points out more than once that peramivir is still being tested and that questions remain about its potential effectiveness. The story points out that the experimental drug is being offered only to patients who are already in the hospital and aren’t being helped by approved drugs. The story did not point out that one of the supporters of faster and broader access to peramivir, Dr. Richard Whitley, has long been a booster of the drug, which is being commercially developed by a spin-off of the University of Alabama department he works in. See Whitley comments in a 2005 article promoting the potential of peramivir: http://main.uab.edu/show.asp?durki=87834 Here we also point out that the story profiled only one patient and includes a quote from the patient’s father crediting peramivir with saving his daughter’s life. The story does not give any examples of similar patients who either survived after getting approved drugs or who received peramivir and yet did not survive. Despite the clear caveats in the story, the reliance on only a single anecdote may give readers a skewed sense of the benefits of the unapproved drug. The story makes clear that the approved antiviral flu drugs are Tamiflu and Relenza. The story makes very clear that peramivir is experimental and is being offered only because some patients cannot take or aren’t helped by approved antiviral drugs. The story is quite clear that peramivir is still being tested. The story does not appear to rely on a news release.
Example Output: New Drug for H1N1 Flu Offers Hope

Example Input: Democrats on a subcommittee of the House of Representatives Committee on Oversight and Reform released a cache of internal Juul emails and other documents that committee staff described as early attempts to “enter schools and convey its messaging directly to teenage children.”   Juul’s use of social media influencers to promote its vaping devices in the years after it launched in 2015 also came under scrutiny. James Monsees, Juul’s co-founder and chief product officer, told the committee that the company’s target audience from the beginning has been adult cigarette smokers. Among efforts cited in the Juul documents released were a $134,000 payment to set up a five-week “holistic health education” summer camp at a Maryland charter school, recruiting children from third through 12th grades, and offering $10,000 to schools using the company’s “youth prevention and education” programs for students, including those caught using e-cigarette products. “You don’t think that sounds strange at all?” Representative Katie Hill, a Democrat, asked Juul’s chief administrative officer, Ashley Gould. “All of these educational efforts were intended to keep youth from using the product,” Gould responded. When Juul realized how the school involvement could be perceived as negative, “we stopped the program,” she said. In a statement after the hearing, Juul said the $134,000 donation was to “facilitate already-existing community outreach and youth-prevention programs,” and said the company “did not have any direct interaction with the students.”  Several committee members said Juul’s initiatives appeared similar to past efforts by the tobacco industry to reach young people under the guise of smoking prevention programs. Gould said Juul, which is 35 percent owned by Marlboro maker Altria Group Inc (MO.N), halted its program last year once it became aware of the tobacco industry’s past moves. Caleb Mintz, 17, a New York city high school student, testified at a separate hearing on Wednesday that a Juul representative came to his school as part of an educational program on mental health and addiction last year. He said in an interview Thursday that students received “mixed messages” about the product, being told it was safe but not to buy it. Mintz said after the hearing that the Juul presentation seemed to be “playing to the side of teens as rebellious. When a teen is told not to do something, they’re more likely to do it.”    Members of the committee also quizzed Gould and Monsees over the use of social media influencers to promote Juul’s vaping devices. Company executives early on agreed that “younger consumers age 25 to 34 was going to be the target of our initial campaign,” Monsees said. “They would be more receptive to new technology solutions,” such as the Juul device. Amid an enormous uptick in teenage use of e-cigarettes in 2018 — a 78% increase among high school students from 2017 to 2018, according to federal data — Juul said it ended all social media advertising last fall. Juul also pulled many flavored nicotine pods, except mint, menthol and tobacco, from retail stores, which Monsees said represented more than half of the company’s sales at that time.
Example Output:
U.S. lawmakers grill e-cigarette maker Juul over efforts targeted at schoolchildren.